Novo Nordisk Agrees to $100 Million Settlement in Insulin Pricing Suit

Novo Nordisk has agreed to a settlement in the amount of $100 million in an insulin pricing lawsuit led by a group of pension and retirement plaintiffs. The sum will be covered by insurance and Novo Nordisk admits no wrongdoing in the agreement.

According to a statement, “Novo Nordisk believes that the plaintiffs’ claims are without any merit, but is settling the lawsuit to avoid the burden, inherent risk and expense of further litigation.” Read more here.

(Source: Hugh Gosling, PMLiVE, 9/28/21)